Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60Leukemia 32Gastrointestinal Stromal Tumors 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 21Blast Crisis 9Philadelphia Chromosome 8Neoplasm Metastasis 8Melanoma 8Lung Neoplasms 8Brain Neoplasms 7Sarcoma 6Prostatic Neoplasms 6Neoplasms 6Recurrence 5Ovarian Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 4Primary Myelofibrosis 4Polycythemia Vera 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myeloid 4Dermatofibrosarcoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Solid Tumors. × Imatinib Mesylate × Clear all
NCT00159016 2011-04-28

Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.

Hadassah Medical Organization

Phase 2 Withdrawn
100 enrolled
Other solid neoplasm

Metastatic Solid Tumors.

Data powered by HemOnc (CC BY 4.0) Colophon âš¡